The Inhibitory Effect of Eupatilin on the Agonist-Induced Regulation of Vascular Contractility

Abstract

The present study was undertaken to investigate the influence of eupatilin on vascular smooth muscle contractility and to determine the mechanism involved. Denuded aortic rings from male rats were used and isometric contractions were recorded and combined with molecular experiments. Eupatilin more significantly relaxed fluoride-induced vascular contraction than thromboxane A₂ or phorbol ester-induced contraction suggesting as a possible anti-hypertensive on the agonist-induced vascular contraction regardless of endothelial nitric oxide synthesis. Furthermore, eupatilin significantly inhibited fluoride-induced increases in pMYPT1 levels. On the other hand, it didn't significantly inhibit phorbol ester-induced increases in pERK1/2 levels suggesting the mechanism involving the primarily inhibition of Rho-kinase activity and the subsequent phosphorylation of MYPT1. This study provides evidence regarding the mechanism underlying the relaxation effect of eupatilin on agonist-induced vascular contraction regardless of endothelial function.

INTRODUCTION

Artemisia asiatica Nakai (family Asteraceae) is an herbal medicine used as a hepatoprotective, antioxidative, anti-inflammatory, and antibacterial agent [1,2]. Eupatilin, a flavone or a type of flavonoid, is isolated from Artemisia asiatica Nakai and used in the treatment of acid-related disorders. We investigated the possible influence and related mechanisms of the anti-inflammatory eupatilin on vascular smooth muscle contractility to develop a better antihypertensive. Denuded aortic rings from male Sprague-Dawley rats were used and isometric contractions were recorded using a computerized data acquisition system. These data were combined with molecular experiments.

Alterations in the arterial tone are frequently associated with cardiovascular diseases constituting an important cause of morbidity and mortality in humans, one of which is hypertension that is a multifactorial disorder that involves many mechanisms including endothelial dysfunction and leading to risk factors for cardiovascular diseases. Besides endothelial dysfunction, it is generally accepted that vascular smooth muscle contractility is predominantly controlled by Ca²⁺ signaling involving Ca²⁺ influx, release or sensitization and regulating a Ca²⁺-dependent increase in the phosphorylation of a 20 kDa myosin light chain (MLC₂₀) [3]. The extent of MLC₂₀ phosphorylation or force of contraction induced by agonist stimulation is usually higher than that caused by an increase in the cytosolic Ca²⁺ concentration referred to as Ca²⁺ sensitization [3]. Subsequent studies suggested that the inhibition of MLC phosphatase by Rho-kinase [4-7] or thin filament regulation including the activation of protein kinase C (PKC), mitogen-activated protein kinase kinases (MEK) and extracellular signal regulated kinase (ERK) 1/2, and phosphorylation of the actin binding protein caldesmon [8] may be major components of the pathway that facilitates in Ca²⁺ sensitization.

In various smooth muscles, fluoride, phorbol ester or thromboxane A₂ mimetic has been shown to induce contractions, which may be due to primarily enhanced Ca²⁺ sensitivity or partially increased Ca²⁺ concentration only in thromboxane A₂ mimetic. In particular, fluoride has been known to induce contractions in blood vessel preparations and to be a potent stimulator of Gs, Gi, Gq and transducin [9-11]. It is possible that the contractions induced by fluoride or thromboxane A₂ mimetic involve the RhoA/Rho-kinase pathway [12]. However, it has not been reported as to whether this pathway is inhibited during eupatilin-induced vascular smooth muscle relaxation in aortic rings precontracted with Rho-kinase activator fluoride or phorbol ester. Therefore, the aim of the present study was to investigate the possible roles of Rho-kinase or MEK inhibition on Ca²⁺ desensitization during the eupatilin-induced relaxation of isolated rat aortas by using RhoA/Rho-kinase activators such as a full activator fluoride or thromboxane A₂ or a partial activator phorbol ester excluding endothelial nitric oxide synthesis.

METHODS

Tissue preparation

Male Sprague-Dawley rats weighing 300~350 g were anesthetized with sodium pentobarbital (50 mg/kg i.p.) as subjected to cervical dislocation, in accord with the procedures approved by the Institutional Animal Care and Use Committee at our institutions. Thoracic aortas were quickly removed and immersed in oxygenated (95% O₂/5% CO₂) physiological saline solution composed of (mM): 115.0 NaCl, 4.7 KCl, 2.5 CaCl₂, 1.2 MgCl₂, 25.0 NaHCO₃, 1.2 KH₂PO₄, and 10.0 dextrose (pH 7.4). They were then freed of all adherent connective tissue, and aortic endothelia were removed by gentle abrasion using a cell scraper.

Contraction measurements

Two stainless-steel triangles were inserted through each vessel ring and each aortic ring was then suspended in a water-jacketed organ bath (10 ml) maintained at 37℃ and aerated with a mixture of 95% O₂ and 5% CO₂. One triangle was anchored to a stationary support, and the other was connected to an isometric force transducer (Grass FT03C, Quincy, Mass., USA). The rings were stretched passively by applying an optimal resting tension of 2.0 g, which was maintained throughout the experiment. Each ring was equilibrated in the organ bath solution for 60 min before contractile responses to 50 mM KCl were measured. Isometric contractions were recorded using a computerized data acquisition system (PowerLab/8SP, AD Instruments, Castle Hill, NSW, Australia).

The direct effect of eupatilin was determined by addition of it after KCl (50 mM), thromboxane A₂ (0.1 µM), phorbol ester (1 µM) or fluoride (8 mM) induced contractions had plateaued in normal Krebs' solution.

Western blot analysis

Muscle strips were quick-frozen by immersion in a dry ice/acetone slurry containing 10% trichloroacetic acid (TCA) and 10 mM dithiothreitol (DTT). Muscles were stored at -80℃ until use. Tissues were brought up to room temperature in a dry ice/acetone/TCA/DTT mixture and then homogenized in a buffer containing 20 mM MOPS, 4% SDS, 10% glycerol, 10 mM DTT, 20 mM β-glycerophosphate, 5.5 µM leupeptin, 5.5 µM pepstatin, 20 kIU aprotinin, 2 mM Na₃VO₄, 1 mM NaF, 100 µM ZnCl₂, 20 µM 4-(2-aminoethyl) benzenesulphonyl fluoride (AEBSF) and 5 mM EGTA. Protein-matched samples (modified Lowry protein assay, DC Protein Assay Kit, Bio-Rad) were electrophoresed on sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE (Protogel, National Diagnostics), transferred to polyvinylidene fluoride PVDF membranes, and subjected to immunostaining and densitometry using appropriate antibodies. The success of protein matching was confirmed by Naphthol Blue Black staining of the membrane and by densitometry of the actin band. Lane loading variations were corrected by normalization versus β-actin. Sets of samples produced during individual experiments were run in the same gel and densitometry was performed on the same film.

Chemicals and antibodies

Drugs and chemicals were obtained from the following sources. Sodium fluoride, KCl, acetylcholine, eupatilin, U-46619 and phorbol 12,13-dibutyrate were purchased from Sigma (St. Louis, MO, USA). DTT, TCA and acetone were obtained from Fisher Scientific (Hampton, NH, USA). Enhanced chemiluminescence (ECL) kits were from Pierce (Rockford, IL, USA). Antibodies against phospho-myosin phosphatase targeting subunit protein 1 (phospho-MYPT1) at Thr855 (1:5,000), MYPT1, ERK or phosphoERK at Thr202/Tyr204 were purchased from Cell Signaling Technology (Danvers, MA, USA) or Upstate Biotechnology (Lake Placid, NY, USA) to determine levels of RhoA/Rho-kinase activity [13,14] or MEK activity. Anti-mouse IgM (goat) and anti-rabbit IgG (goat), conjugated with horseradish peroxidase, were used as secondary antibodies (1:2,000 and 1:2,000, respectively, Upstate, Lake Placid, NY). Eupatilin was prepared in dimethyl sulfoxide (DMSO) as a 100 mM stock solution and frozen at -20℃ for later use. DMSO alone had no observable effect at concentrations used (data not shown).

Statistics

The data were expressed as mean±standard error of the mean (SEM). The student's unpaired t test was used to determine the statistical significance of the means between two groups using SPSS 12.0 (SPSS Inc., Chicago, Illinois, U.S.A.). p-values<0.05 were regarded as statistically significant.

RESULTS

Effect of eupatilin on contractions of endothelium-denuded aortas induced by a full RhoA/Rho-kinase activator fluoride or thromboxane A₂

Endothelium was removed by gentle abrasion with a cell scraper to identify the direct effect of eupatilin on vascular smooth muscle. The absence of endothelium was confirmed by a lack of relaxation after treating precontracted ring segments with acetylcholine (1 µM). Eupatilin showed no significant effect on basal tension (data not shown), but significantly inhibited the contraction induced by a full activator fluoride at a low concentration regardless of endothelial nitric oxide synthesis (Fig. 1, 2). This suggests that the relaxation mechanism of eupatilin might involve the inhibition of Rho-kinase activity in addition to endothelial nitric oxide synthesis and the subsequent activation of guanylyl cyclase. Coincidentally, eupatilin at the same concentration slightly inhibited thromboxane A₂ mimetic U46619-induced contraction (Fig. 1, 3) suggesting that thromboxane A₂ mimetic acts differently from a full activator where Rho-kinase activation was the main pathway.

Fig. 1.

A representative tracing of eupatilin-induced relaxation on the fluoride- (A), thromboxane A2- (B) or phorbol ester- (C) induced vasoconstriction in rat aorta.

Fig. 2.

Effect of eupatilin on fluoride-induced vascular contraction. Each ring was equilibrated in the organ bath solution for 30~60 min before relaxation responses to eupatilin were measured. Data are expressed as the means of 3~5 experiments with vertical lines representing SEMs. Control respectively. ^*p<0.05, ^**p<0.01 versus.

Fig. 3.

Effect of eupatilin on thromboxane A₂-induced vascular contraction. Each ring was equilibrated in the organ bath solution for 30~60 min before relaxation responses to eupatilin were measured. Data are expressed as the means of 3~5 experiments with vertical lines representing SEMs. Control respectively. ^*p<0.05.

Effect of eupatilin on the contractions of denuded aortas induced by a partial RhoA/Rho-kinase activator phorbol ester

The vasoconstrictors used have been proved to be partial RhoA/Rho-kinase activators (data not shown). Interestingly, phorbol 12,13-dibutyrate-induced contraction was slightly inhibited by eupatilin at a high concentration regardless of endothelial nitric oxide synthesis (Fig. 1, 4), which suggested that other pathways including thin or actin filament regulation were slightly inhibited.

Fig. 4.

Effect of eupatilin on phorbol ester-induced vascular contraction. Each ring was equilibrated in the organ bath solution for 30~60 min before relaxation responses to eupatilin were measured. Data are expressed as the means of 3~5 experiments with vertical lines representing SEMs. Control respectively. ^*p<0.05.

Effect of eupatilin on the level of MYPT1 phosphorylation at Thr-855

To confirm the role of eupatilin on the thick filament regulation of smooth muscle contractility, we measured levels of myosin phosphatase targeting subunit 1 (MYPT1) and phospho-MYPT1 in muscles quick frozen after 60 min exposure to eupatilin for the equilibration. Each relaxing ring was precontracted with 8 mM fluoride. This work was done using quick frozen eupatilin (0.1 mM)-treated rat aortas in the absence of endothelium and the levels were compared to those of vehicle-treated rat aortas (Fig. 5). Interestingly, a significant decrease in fluoride-induced MYPT1 phosphorylation at Thr855 was found to be led by eupatilin (Fig. 5). Thus, thick or myosin filament regulation including myosin phosphatase activation via RhoA/Rho-kinase inactivation might be involved in the reduced contractility of eupatilin-treated rat aorta. Thus, the intensity of relaxation seems to directly proportional to the level of inhibition of MYPT1 phosphorylation by eupatilin.

Fig. 5.

Effect of eupatilin on fluoride-induced increases in phospho-MYPT1 levels. Phospho-MYPT1 protein levels were significantly decreased in quick frozen eupatilin-treated rat aorta in the absence of endothelium compared to vehicle-treated rat aorta precontracted with fluoride. The upper panel shows a typical blot and the lower panel shows average densitometry results for relative levels of phospho-MYPT1. Data are expressed as the means of 3~5 experiments with vertical lines representing SEMs. ^**p<0.01, ^##p<0.01, versus control or normal group respectively. Eupa: 0.1 mM eupatilin; NaF: 8 mM sodium fluoride.

Effect of eupatilin on levels of ERK1/2 phosphorylation at Thr-202/Tyr-204

To confirm the role of eupatilin on thin filament regulation of smooth muscle contractility, we measured levels of ERK1/2 and phospho-ERK1/2 in muscles quick frozen after 60 minutes of exposure to eupatilin for the equilibration. Each relaxing ring was precontracted with 1 µM phorbol ester (phorbol 12,13-dibutyrate). As compared with vehicle-treated rat aortas, no significant decrease in ERK 1/2 phosphorylation at Thr202/Tyr204 was led by eupatilin in these eupatilin (0.1 mM)-treated rat aortas in the absence of endothelium (Fig. 6) showing partial vasorelaxation (Fig. 4) and weak thin filament regulation. These findings show that thin or actin filament regulation including ERK1/2 phosphorylation via MEK activation might be of lesser importance in the decreased contractility induced by eupatilin at a low concentration (0.03 mM).

Fig. 6.

Effect of eupatilin on phorbol ester-induced increases in phospho-ERK1/2 levels. Phospho-ERK1/2 protein levels were not decreased in quick frozen eupatilin-treated rat aortas in the absence of endothelium compared to vehicle-treated rat aortas precontracted with phorbol ester. The upper panel shows a typical blot and the lower panel shows average densitometry results for relative levels of phospho-ERK1/2. Data are expressed as the means of 3~5 experiments with vertical lines representing SEMs. ^##p<0.01, versus normal group respectively. Eupa: 0.1 mM eupatilin; PDBu: 1 µM phorbol 12,13-dibutyrate.

DISCUSSION

The present study demonstrates that eupatilin can modulate the vascular contractility in an agonist-dependent manner. Interestingly, the mechanism involved seems to be not only endothelium-dependent but also to involve the inhibition of Rho-kinase and the partial inhibition of MEK activity. Eupatilin has been previously recognized for its anti-inflammatory activity. Therefore, we investigated whether the inhibition of RhoA/Rho-kinase or MEK activity contributes to eupatilin-induced vascular relaxation in rat aortas denuded and precontracted by a full RhoA/Rho-kinase activator fluoride or thromboxane A₂ or by a partial activator phorbol ester.

The mechanism by which fluoride activates G-proteins has been established [9-11]. It has been reported that the effect of fluoride on heterotrimeric G protein is due to the formation of AlF₄^- from fluoride and contamination of glassware [15,16], which mimics the effect of GTP [17]. Fluoride is also a classical Ser/Thr phosphatase inhibitor [18] and is routinely included in extraction buffers to prevent the dephosphorylations of proteins at Ser and Thr residues by endogenous phosphatases. On the other hand, previous studies that examined the mechanisms underlying arterial contractions induced by the phorbol ester or thromboxane A₂ have reported variable findings with regard to the contraction triggered by Rho-kinase activation [13,19]. These findings are consistent with the notion that eupatilin can decrease fluoride, phorbol ester or thromboxane A₂ induced contraction by inhibiting Rho-kinase activity.

The mechanisms by which Rho-kinase activation causes vascular contraction is an area of intense study, and several possibilities exist. For example, Rho-kinase phosphorylates myosin light chain phosphatase, which decreases phosphatase activity and causes a buildup of phosphorylated myosin light chains [20,21]. Rho-kinase has also been demonstrated to phosphorylate myosin light chains directly and independently of myosin light chain kinase and phosphatase activity [22]. Recently, Rho-kinase was found to be involved in vascular contractions evoked by fluoride, phorbol ester or thromboxane A₂ [12,13,19].

The present study demonstrates that eupatilin ameliorates the maximal or submaximal contraction induced by vasoconstrictor fluoride, thromboxane A₂ or phorbol ester endothelium-independently (Fig. 1~4), and that this ameliorative mechanism primarily involves the RhoA/Rho-kinase pathway. Previously, most vasodilation was believed to be caused by endothelial nitric oxide synthesis and the subsequent activation of guanylyl cyclase. In the present study, eupatilin at a low concentration significantly inhibited fluoride-induced contraction regardless of endothelial function (Fig. 2), but not thromboxane A₂- or phorbol ester-induced contraction (Fig. 3, 4). This suggests that the vascular contractions elicited by RhoA/Rho-kinase activators such as a full activator fluoride and a partial activator phorbol ester are achieved via different mechanisms (Fig. 5, 6). Therefore, we postulated that pathways other than the RhoA/Rho-kinase pathway might be involved in Ca²⁺ sensitization induced by the phorbol ester. Thus, eupatilin at a low concentration might not inhibit Ca²⁺ mobilization [23,24] or the phosphorylation of extracellular signal-regulated kinase (ERK), protein kinase C-potentiated inhibitory protein for protein phosphatase type 1 (CPI-17) or integrin-linked kinase (ILK) [25,26]. Furthermore, eupatilin decreased phosphorylation of MYPT1 at Thr855 induced by fluoride (Fig. 5), suggesting the inhibition of Rho-kinase activity as the major mechanism. However, eupatilin at the high concentration didn't significantly decrease the phosphorylation of ERK1/2 induced by phorbol ester (Fig. 6) with partial relaxation (Fig. 4) suggesting the inhibition of MEK activity as a minor mechanism.

In summary, eupatilin at a low concentration significantly attenuates the contractions induced by a full activator fluoride regardless of endothelial function. In contrast, a partial activator phorbol ester-induced contraction was not significantly inhibited by eupatilin at this low concentration suggesting additional Ca²⁺ mobilization or the phosphorylations of ERK, CPI-17, ILK or ZIPK required for the partial activator-induced contractions. Thus, the mechanism underlying the relaxation induced by eupatilin at a low concentration in fluoride-induced contractions involves the inhibition of Rho-kinase activity and not the inhibition of MEK activity. Interestingly, during phorbol ester-induced contraction, no inhibition of MEK activity and subsequent ERK1/2 phosphorylation induced by eupatilin at a high concentration suggest that MEK activity is not importantly required for relaxation. In conclusion, in addition to endothelial nitric oxide synthesis, Rho-kinase inhibition makes a major contribution to the mechanism responsible for eupatilin-induced vasorelaxation in denuded muscle.

ABBREVIATIONS

ERK

extracellular signal regulated kinase

MLC

myosin light chain

PKC

protein kinase C

MEK

mitogen-activated protein kinase kinase

MYPT1

myosin phosphatase targeting subunit 1